Metformin Inhibits Inflammation by Targeting the NLRP3 Inflammasome: Linking NF-κB/NEK7/AMPK Signaling to Mitochondrial Function
Journal of Inflammation Research · 2026-03 · Volume 19 · 1-22
DOI: 10.2147/jir.s570735 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inflammation Research, 2026-03. Verfasst von Dingyi Ning und 11 weiteren Autor:innen. Beteiligte Einrichtung: Queen Mary School, Nanchang University, Nanchang, 330006, People's Republic of China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Metformin, the first-line treatment for type 2 diabetes, has significant anti-inflammatory functions in addition to controlling blood glucose levels. Although metformin has been proven to inhibit NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome, the function of mitochondria in this effect has not been fully studied. This review summarizes studies on metformin that could regulate inflammation progression through the Toll-like Receptor 4/Nuclear Factor Kappa B (TLR4/NF-κB) pathway, NIMA-related kinase 7 (NEK7) pathway, AMPK pathway, and Janus kinase 2-Signal Transducer and Activator of Transcription (JAK2-STAT) pathway, with the involvement of mitochondria. The effects of metformin on the mitochondria block the key steps of NLRP3 inflammation activation, including NEK7 assembly, reactive oxygen species (ROS) activation, reduced thioredoxin-interacting protein (TXNIP) expression, and caspase 1-mediated IL-1β/IL-18 maturation. Importantly, we propose that metformin improves the pathological development of common multi-organ diseases by regulating NLRP3-inflammation pathways. These findings highlight the promising treatment potential of metformin in diseases driven by inflammasomes and make it meaningful to implement clinical trials to evaluate its efficacy in NLRP3 inflammasome-driven pathologies beyond diabetes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Queen Mary School, Nanchang University, Nanchang, 330006, People's Republic of China.
- The Second Clinical Medical College of Nanchang University, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang, 330006, People's Republic of China.
- The First Clinical Medical College of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang, 330006, People's Republic of China.
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang, China; Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, Nanchang, 330006, People…
- Food and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong, Hong Kong, People's Republic of China.
Zitieren
APA
Ning, D., Jiang, C., Zeng, J., Zeng, F., Zheng, X., Xia, P., Liu, Y., Huang, X., Zhang, D., Liu, X., Zhang, J., & Yu, P. (2026). Metformin Inhibits Inflammation by Targeting the NLRP3 Inflammasome: Linking NF-κB/NEK7/AMPK Signaling to Mitochondrial Function. Journal of Inflammation Research, Volume 19, 1-22. https://doi.org/10.2147/jir.s570735
Vancouver
Ning D, Jiang C, Zeng J, Zeng F, Zheng X, Xia P, et al. Metformin Inhibits Inflammation by Targeting the NLRP3 Inflammasome: Linking NF-κB/NEK7/AMPK Signaling to Mitochondrial Function. Journal of Inflammation Research. 2026;Volume 19:1-22. doi:10.2147/jir.s570735
BibTeX
@article{Ning2026,
author = {Ning, Dingyi and Jiang, Chenxin and Zeng, Jiangyan and Zeng, Fanyun and Zheng, Xuehong and Xia, Panpan and Liu, Yunkun and Huang, Xin and Zhang, Deju and Liu, Xiao and Zhang, Jing and Yu, Peng},
title = {Metformin Inhibits Inflammation by Targeting the NLRP3 Inflammasome: Linking NF-κB/NEK7/AMPK Signaling to Mitochondrial Function},
journal = {Journal of Inflammation Research},
year = {2026},
volume = {Volume 19},
pages = {1--22},
doi = {10.2147/jir.s570735}
}
EUVIMED